Sabby Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sabby Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,312	Closed	-$4.99M	–	152
2018 Q3	$4.99M	Buy	1,312 +476	+57%	+$21.1K	0.64%	27
2018 Q2	$3.78M	Buy	836 +78	+10%	+$3.55K	0.58%	27
2018 Q1	$3.66M	Buy	+758	New	+$42.3K	0.44%	28
2017 Q4	–	Sell	-301	Closed	-$935K	–	203
2017 Q3	$935K	Sell	301 -369	-55%	-$10.4K	0.06%	78
2017 Q2	$1.83M	Buy	670 +265	+65%	+$7.88K	0.12%	71
2017 Q1	$1.49M	Buy	+405	New	+$10.2K	0.08%	110
2016 Q4	–	Sell	-721	Closed	-$1.66M	–	340
2016 Q3	$1.66M	Buy	721 +300	+71%	+$5.72K	0.06%	147
2016 Q2	$698K	Sell	421 -5,206	-93%	-$105K	0.04%	195
2016 Q1	$8.92M	Buy	+5,627	New	+$100K	0.45%	26

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's GBT Position: Q3 2016 in Review

Sabby Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2016, closing a stake of 254,029 shares — an estimated $4.84M sold.

Sabby Management first reported a position in GBT in Q3 2015 and held it in 4 quarters. The position peaked at $14.5M in Q3 2015. 84 funds tracked by Wall St. Rank hold GBT as of Q3 2016.

Sabby Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2016 after selling out during the quarter.
Sabby Management sold 254,029 Global Blood Therapeutics, Inc. shares in Q3 2016, an estimated $4.84M.
Sabby Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 4 quarters.
Sabby Management's Global Blood Therapeutics, Inc. position peaked at $14.5M in Q3 2015.
84 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.